View : 451 Download: 116
Oral Nanomedicines for siRNA Delivery to Treat Inflammatory Bowel Disease
- Title
- Oral Nanomedicines for siRNA Delivery to Treat Inflammatory Bowel Disease
- Authors
- Shinn, Jongyoon; Lee, Juyeon; Lee, Seon Ah; Lee, Seon Ju; Choi, Ah Hyun; Kim, Jung Seo; Kim, Su Jin; Kim, Hyo Jin; Lee, Cherin; Kim, Yejin; Kim, Joohyeon; Choi, Jonghee; Jung, Byungchae; Kim, Taeho; Nam, HyeonTaek; Kim, Hyungjun; Lee, Yonghyun
- Ewha Authors
- 이용현
- SCOPUS Author ID
- 이용현
- Issue Date
- 2022
- Journal Title
- PHARMACEUTICS
- ISSN
- 1999-4923
- Citation
- PHARMACEUTICS vol. 14, no. 9
- Keywords
- oral drug delivery; siRNA; inflammatory bowel disease; gene delivery; nanomedicines; Immunotherapy
- Publisher
- MDPI
- Indexed
- SCIE; SCOPUS
- Document Type
- Review
- Abstract
- RNA interference (RNAi) therapies have significant potential for the treatment of inflammatory bowel diseases (IBD). Although administering small interfering RNA (siRNA) via an oral route is desirable, various hurdles including physicochemical, mucus, and cellular uptake barriers of the gastrointestinal tract (GIT) impede both the delivery of siRNA to the target site and the action of siRNA drugs at the target site. In this review, we first discuss various physicochemical and biological barriers in the GI tract. Furthermore, we present recent strategies and the progress of oral siRNA delivery strategies to treat IBD. Finally, we consider the challenges faced in the use of these strategies and future directions of oral siRNA delivery strategies.
- DOI
- 10.3390/pharmaceutics14091969
- Appears in Collections:
- 약학대학 > 약학과 > Journal papers
- Files in This Item:
-
pharmaceutics-14-01969-v2.pdf(3.6 MB)
Download
- Export
- RIS (EndNote)
- XLS (Excel)
- XML